imp 2

IMP2-IN-1 (compound 4) is an effective IMP2 inhibitor with an IC50 of 81.3-127.5 μM for IMP2 RNA, reducing IMP2 levels in SW480 cells and significantly inhibiting the activity of both differentiated and undifferentiated Huh7 cells.

IMP2-IN-2 is a potent and selective inhibitor of IMP2 with IC50 values of 120.9 μM and 236.7 μM for the inhibition of IMP2 interaction with RNA_A and RNA_B, respectively. IMP2-IN-2 can be used in cancer research.

IMP2-IN-3, a potent IMP2 inhibitor, demonstrates anticancer effects [1].

NLRP3/AIM2-IN-3 is a unique molecule that inhibits NLRP3 and AIM2 inflammasome activation in a species-specific manner. It has an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 is a potent inhibitor of NLRP3 and AIM2 inflammasome-dependent cell lysis with an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 inhibits LPS/nigericin NLRP3/AIM2-IN-3 inhibits LPS/nigericin-stimulated cell lysis in THP-1 macrophages with an IC50 value of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 interferes with the interaction of NLRP3 or AIM2 with the bridging protein ASC, inhibiting oligomerization of ASC.

Taurochenodeoxycholic Acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid.

Taurochenodeoxycholic acid sodium (Sodium taurochenodeoxycholate) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. It can increase glucose-induced insulin secretion and stimulate the electrical activity of α2-cells and enhance cytosolic Ca(2+) concentration ([Ca(2+)](c)).

NLRP3/AIM2-IN-2 is a novel potent inhibitor with different species-specific effects on NLRP3 and AIM2 inflammasome dependent pyroptosis with IC50 of 0.2392 ± 0.0233 μ M.

AIMP2-DX2-IN-1 is a potent AIMP2-DX2 inhibitor with potential antitumor activity for the study of lymphoma.

BC-DXI-843 is inhibitor of AIMP2-DX2, and is potential for development of novel therapeutics targeting AIMP2-DX2 in lung cancer.

Inosine 5'-monophosphate disodium salt hydrate (Inosine 5'-monophosphate disodium salt), or inosinic acid, is the ribonucleotide of hypoxanthine and the first nucleotide formed during purine synthesis.

IMB-XH1 (Mcl1-IN-2) is a myeloid cell factor 1 (Mcl-1) inhibitor.

Metallo-β-lactamase-IN-16 (compound 18), a sulfone-containing metallo-β-lactamase inhibitor, exhibits antimicrobial activity. It effectively inhibits various metallo-β-lactamases, including NDM-1 (New Delhi metallo-β-lactamase-1), IMP-1 (imipenemase-1), VIM-1 (Verona Integron-encoded Metallo-β-lactamase), and VIM-2. The IC50 values for these enzymes are 0.16 nM, 0.23 nM, 0.31 nM, and 1.0 nM respectively.

ATIC-IN-2 (Compound 1) is a competitive inhibitor of the bifunctional enzyme AICAR transformylase/IMP cyclohydrolase (ATIC) that binds to the inosine monophosphate cyclohydrolase (IMPCH) domain with a Ki value of 0.13 μM, ATIC-IN-2 is commonly employed in purine biosynthesis research to dissect nucleotide metabolism, enzyme regulation, and metabolic vulnerabilities in cancer cells.

epi-D-Captopril (epi-D-SQ 14225) is a stereoisomer of Captopril and functions as an inhibitor of metallo-beta-lactamases (MBLs). The IC50 values of epi-D-Captopril for NDM-1, IMP-1, and VIM-2 are 64 μM, 173 μM, and 5.5 μM, respectively. This compound holds potential for research in MBLs-related antibiotic-resistant infections.

Metallo-β-lactamase-IN-12 is a dual inhibitor targeting Metallo-β-lactamase [MβLs (NDM-1, IMP-1)] and Serine β-lactamase [SβLs (OXA-48, KPC-2)], displaying IC50 values of 0.64 μM, 1.32 μM, 1.01 μM, and 0.57 μM respectively. Metallo-β-lactamase-IN-12 also exhibits antibacterial activity.

Cyclic di-IMP (sodium salt) (c-di-IMP) is a synthetic second messenger structurally related to the bacterial second messengers cyclic di-GMP and cyclic di-AMP . C-di-IMP has adjuvant properties when co-administered with antigens in vitro and by mucosal routes in vivo. C-di-IMP enriches the population of MHC class I and II, CD80, CD86, CD40, and CD54 positive dendritic cells derived from murine bone marrow. It also stimulates macrophages at 500 ng/ml. Mice immunized with β-galactosidase (β-gal) plus c-di-IMP through the intranasal route show a humoral immune response, evidenced by an increase in IgG titers up to 2-fold compared to mice immunized with β-gal alone. Mice immunized with β-gal plus c-di-IMP also exhibit a Th1/Th2 response, indicating that the adjuvant activity of c-di-IMP leads to a cellular immune response as well.

Metallo-β-lactamase-IN-8 (compound 17) is a potent, reversible, and competitive broad-spectrum metallo-β-lactamases (MβLs) inhibitor with antibacterial activity, exhibiting IC50 values of 1.3 μM against L1, 5.7 μM against ImiS, 9.8 μM against IMP-1, and 9.9 μM against VIM-2 [1].

YJ182 is an NDM-1 inhibitor with an IC50 of 0.23 μM, and additionally inhibits IMP-1, VIM-2, GIM-1, and MMP-2 with respective IC50 values of 0.25, 0.61, 0.49, and 6.92 μM. It is utilized in bacterial infection research [1].

Metallo-β-lactamase-IN-15 (Compound ±13), a potent inhibitor of MBL, demonstrates IC 50 values of 0.29 μM for NDM-1, 0.088 μM for IMP-1, and 0.063 μM for VIM-2, respectively [1].